

Six-month Follow-up on 50 Consecutive Patients with Intravitreal Bevacizumab Injections for Neovascular Age Related Macular Degeneration

Samira Khan, (Albany, NY), Paul M. Beer, MD (Albany, NY), Naomi S. Falk, MD (Albany, NY), Amjad Hammad, MD (Albany, NY), Martin O'Malley, MD (Albany, NY)

PURPOSE

6 months results of intravitreal Bevacizumab on patients with neovascular ARMD.

METHODS

A retrospective chart review of 50 consecutive patients who have received at least one intravitreal injection of bevacizumab for neovascular age-related macular degeneration.

RESULTS

Pre-injection mean OCT is 373 microns and mean visual acuity is 20/100. At 1 month following initial injection, mean OCT is 244 microns and mean visual acuity is 20/70. At 3 months, mean OCT is 272 microns and mean visual acuity is 20/70. At 6 month follow-up, mean OCT is 290 microns and mean visual acuity is 20/80. Complications that occurred following administration of Bevacizumab include 1 patient with acute endophthalmitis, 1 patient with a retinal detachment and 1 patient who developed keratic precipitates.

CONCLUSION

In comparison to baseline, intravitreal Bevacizumab has lead to an improvement in both OCT and vision at 1 month following initial injection. At 3 and 6 months post injection the initial benefit is slightly diminished.